Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Vertex Pharmaceuticals is teaming up with Johnson & Johnson and GlaxoSmithKline in separate partnerships aimed at developing an all-oral hepatitis C treatment. Vertex and J&J’s Janssen Pharmaceuticals unit will conduct a Phase II study of a treatment combining Vertex’ polymerase inhibitor VX-135 and Janssen’s protease inhibitor simeprevir. Vertex and GSK will study a combination of VX-135 with GSK’s NS5A inhibitor GSK2336805. Last year, FDA approved Vertex’ Incivek protease inhibitor, but, like other hepatitis C drugs, it must be administered with unpleasant interferon injections.
This article has been sent to the following recipient: